| |
Wednesday, March 26, 2025 | 12pm ET / 9am PT Join us for this exclusive webinar to gain actionable insights from industry experts on the top challenges of HCP engagement and latest strategies for driving commercial success. Register today.
|
|
Today’s Big NewsMar 14, 2025 |
|
Wednesday, March 26, 2025 | 2pm ET / 11am PT Understanding a molecule’s characteristics early in development helps minimize challenges and streamline the path to manufacturing. This webinar will explore key considerations in developability assessment, the role of in silico tools in molecular evaluation, and strategies for improving data security in the process. Register now to join us.
|
|
| By Angus Liu Synthetic biology specialist Gro Biosciences, born out of the George Church Lab at Harvard, is exploring strategic alternatives only about half a year after raising a series B backed by top venture capital funds, Fierce Biotech has learned. |
|
|
|
By James Waldron Sutro Biopharma is undergoing a seismic shake-up—jettisoning its CEO, half of its workforce, its lead candidate and its manufacturing facility in a major bid to save cash. |
By James Waldron With Concentra Biosciences expanding its stock influence on Pliant Therapeutics and Acelyrin, the two biotechs have shored up their corporate defences against a potential acquisition. |
By Darren Incorvaia,Zoey Becker Gilead’s Sandra Patterson has “decided to leave the company” after two years in the SVP corporate controller and chief accounting officer role, according to a company filing. Patterson was also Gilead’s principal accounting officer. In her place, the company’s board tapped Diane Wilfong in an interim position amid the search for a permanent successor. |
|
Thursday, March 27, 2025 | 3pm ET / 12pm PT The way healthcare providers are navigating medication access is evolving rapidly, making it critical for pharma brands to keep up. Join us for this deep dive into the latest strategies and tools that can be seamlessly integrated into HCP workflows, while also driving efficiency, improved patient outcomes, and measurable impact. Register now.
|
|
By Darren Incorvaia Researchers at Waseda University in Japan have identified a gene that, when rendered nonfunctional in mice, causes the rodents to develop telltale signs of the liver disease metabolic dysfunction-associated steatohepatitis (MASH). The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be worthwhile targets for new MASH therapies. |
By Dave Muoio March 13 orders from two federal judges require several federal agencies to unwind probationary worker terminations. |
By Fraiser Kansteiner Having spent the better part of the decade grappling with bankruptcy bids and opioid settlements, troubled drugmakers Mallinckrodt and Endo have decided to join forces to create a more flexible company and ultimately spin off their sizeable generics businesses. |
By Noah Tong Follow along today for ongoing coverage of Dr. Oz’s confirmation hearing in front of the Senate Finance Committee. It is likely he will be asked about cuts to Medicaid, potential conflicts of interest, his views on Medicare Advantage and more. |
By Andrea Park,Fraiser Kansteiner,Kevin Dunleavy This week on "The Top Line," we dissect the unprecedented revenue growth enjoyed by many major pharma companies in 2024’s fourth quarter. |
By Angus Liu Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an FDA-approved PD-L1 inhibitor. Japan's Ono Pharmaceutical bought an antisense oligonucleotide from Ionis. Plus more. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we dissect the unprecedented revenue growth enjoyed by many major pharma companies in 2024’s fourth quarter. |
|
|---|
|
|
|
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now.
|
|
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
